Bristol Myers Gains on Results
Bristol Myers Squibb (NYSE: BMY) today presented results from COLLIGO-HCM, a global retrospective real-world data study, in an oral session at the European Society of Cardiology(ESC) Congress 2025 in Madrid.
The analysis showed that Camzyos (mavacamten) was associated with reductions in left ventricular outflow tract (LVOT) obstruction and improvements in symptom burden in a racially diverse population of patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) treated in an international, real-world setting.
The effectiveness and safety demonstrated in COLLIGO-HCM are consistent with results from randomized, controlled clinical trials and further support the growing body of evidence for Camzyos, the first and only approved cardiac myosin inhibitor, as a standard of care for New York Heart Association (NYHA) class II-III symptomatic oHCM.
“Obstructive HCM can lead to considerable negative impact on patients’ lives," said Arnon Adler, MD, staff cardiologist at the Peter Munk Cardiac Centre at University Health Network and associate professor at the University of Toronto.
“These global real-world outcomes data, which are consistent with results from clinical trials, reinforce the overall effectiveness and safety profile of Camzyos and its benefits for diverse global patient groups, including those that are often underrepresented in clinical trials.”
BMY shares rose 32 cents, or 0.7%, Friday to $47.20.
